$0.49
0.00% day before yesterday
Nasdaq, Aug 30, 01:42 am CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.49
-0.09 15.97% 1M
-0.25 34.45% 6M
-0.14 22.69% YTD
-0.36 42.27% 1Y
-14.77 96.82% 3Y
-24.98 98.10% 5Y
-167.59 99.71% 10Y
-167.59 99.71% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.02 3.65%

Key metrics

Basic
Market capitalization
$8.4m
Enterprise Value
$12.0m
Net debt
$3.6m
Cash
$3.1m
Shares outstanding
16.8m
Valuation (TTM | estimate)
P/E
0.4 | 2.6
P/S
4.2 | 56.1
EV/Sales
6.0 | 80.0
EV/FCF
negative
P/B
0.2
Financial Health
Equity Ratio
-8.1%
Return on Equity
-1,281.2%
ROCE
-83.4%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$2.0m | $149.4k
EBITDA
$-35.7m | $7.2m
EBIT
$-35.9m | $-22.7m
Net Income
$72.5m | $3.1m
Free Cash Flow
$-22.1m
Growth (TTM | estimate)
Revenue
-34.1% | -95.0%
EBITDA
41.0% | 116.7%
EBIT
42.5% | 49.1%
Net Income
202.0% | -90.4%
Free Cash Flow
55.1%
Margin (TTM | estimate)
Gross
-57.1%
EBITDA
-1,791.7% | 4,846.4%
EBIT
-1,801.1%
Net
3,635.2% | 2,060.5%
Free Cash Flow
-1,106.1%
More
EPS
$1.4
FCF per Share
$-1.3
Short interest
0.9%
Employees
39
Rev per Employee
$80.0k
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a PAVmed, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a PAVmed, Inc. forecast:

Buy
88%
Hold
13%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.99 1.99
34% 34%
100%
- Direct Costs 3.13 3.13
54% 54%
157%
-1.14 -1.14
70% 70%
-57%
- Selling and Administrative Expenses 30 30
33% 33%
1,497%
- Research and Development Expense 4.78 4.78
61% 61%
240%
-36 -36
41% 41%
-1,794%
- Depreciation and Amortization 0.19 0.19
90% 90%
10%
EBIT (Operating Income) EBIT -36 -36
43% 43%
-1,804%
Net Profit 72 72
202% 202%
3,641%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
PRNewsWire
5 days ago
Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced Lishan Aklog, M.D.
Neutral
PRNewsWire
6 days ago
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the technology NEW YORK , Aug. 26, 2025 /PRNewswire/ --  PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology ...
Neutral
PRNewsWire
18 days ago
Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, relaunched development of implantablephysiological monitor, and initiated integration steps to launch commercial phase withOSU-The James Conference call and webcast to be held today, August 14, at 8:30...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 39
Founded 2014
Website pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today